인투셀

287840KOSDAQ자연과학 및 공학 연구개발업

42.5 / 100

Reference Date: 2026-04-13

Financial Score11.0 / 40

News Sentiment17.5 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, Revenue is on a declining trend. Plunged 19.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

IntuCell is an ADC platform technology company specializing in linker and drug development, leveraging its OHPAS linker and PMT platform technologies to enhance drug delivery efficiency and selectivity. The company utilizes proprietary drug technologies such as Duocarmycin and Nexatecan to establish a competitive edge in oncology, with a pipeline including the B7-H3-targeting ADC candidate ITC-6146RO.

Number of Employees

—

Average Salary

—

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

—Industry Average 3.823.5Point

ROE

-65.72Industry Average -32.113.5Point

2.0x industry avg (excellent)

Debt Ratio

53.66Industry Average 7.520.0Point

7.1x industry avg (risky)

Trend 2024~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼20.9% (1-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼5.2% (1-year basis)

ROE Trend

0.0 / 4

Avg ROE -80.6% (improving, 2yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 70

Positive
인투셀, ADC 신약 ‘ITC-6146RO’ 글로벌 임상 1상 본격화
인투셀은 ADC 신약 후보물질 'ITC-6146RO'의 글로벌 임상 1상에서 첫 환자 투여를 성공적으로 마치며 임상 단계 기업으로 도약했습니다.
Positive
"ADC 넘어 신약후보 물질 개발 확대"
인투셀은 고형암 치료 후보물질 'ITC-6146RO'의 임상 돌입을 시작으로 ADC 플랫폼 전문 기업에서 파이프라인 개발 전문 기업으로 전환을 목표하고 있습니다.

Detailed Momentum

52-week position3.0Point

52w lower range (33%)

Current 39,000Won52-week high 71,00052-week low 22,800

1-month return0.0Point

1m -19.00% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral주식매수선택권부여에관한신고2026-03-26
Neutral정기주주총회결과2026-03-26
Neutral감사보고서제출2026-03-18
Neutral사업보고서 (2025.12)2026-03-18